Gatti J M, Stephenson R A
Division of Urology, University of Utah Health Sciences Center, Salt Lake City, USA.
Urol Clin North Am. 1998 Aug;25(3):397-403. doi: 10.1016/s0094-0143(05)70030-6.
Treatment of testis cancer has improved dramatically over the last 25 years with cure rates that now approach 95%. This success in treatment is the result of multimodal therapy that may include cisplatinum-based chemotherapy, surgery, and radiotherapy. Although there is little dispute that chemotherapy is appropriate as initial treatment for advanced testis cancer, controversy remains regarding the management of early stage B and stage A testis cancer. In part, the current controversy is driven by the performance characteristics of presently available staging methods, that may include serum markers, histologic parameters from orchietomy specimens, and radiographic imaging. This article reviews the performance characteristics and use of these staging methods.
在过去25年里，睾丸癌的治疗取得了显著进展，治愈率如今已接近95%。治疗的成功得益于多模式疗法，其中可能包括以顺铂为基础的化疗、手术和放疗。尽管化疗作为晚期睾丸癌的初始治疗方法几乎没有争议，但早期B期和A期睾丸癌的管理仍存在争议。目前的争议部分是由现有分期方法的性能特征驱动的，这些方法可能包括血清标志物、睾丸切除标本的组织学参数和影像学检查。本文回顾了这些分期方法的性能特征及应用。
